PASG shareholders face extreme dilution to ~7% ownership; the stock will likely reprice toward the implied stub value plus CVR optionality. Watch for the S-4 registration statement detailing the exchange ratio and any stockholder litigation. The deal's success hinges on REM-422 clinical data readouts in mid-2027 and PIPE closing.
Price Chart
Executive Summary
Passage Bio announced a definitive all-stock merger with Remix Therapeutics, where pre-merger Passage shareholders will own only ~7% of the combined company, while Remix shareholders (including PIPE investors) will own ~93%. The deal is supported by an oversubscribed $100M+ private placement led by Decheng Capital, funding the combined entity into 2028 to advance Remix's lead program REM-422, an oral MYB mRNA degrader showing a 43% ORR in adenoid cystic carcinoma. Passage shareholders also receive contingent value rights tied to legacy gene therapy milestones.
Key Financial Metrics
Key Facts
- Pre-merger Passage Bio shareholders expected to own approximately 7% of the combined company at closing.
- Pre-merger Remix shareholders, including PIPE participants, expected to own approximately 93%.
- Concurrent oversubscribed private placement led by Decheng Capital with total gross proceeds of over $100M.
- Combined company expected to have cash runway into 2028.
- Remix's lead program REM-422 (oral MYB mRNA degrader) showed 43% overall response rate and 100% disease control rate in biomarker-positive ACC patients at RP2D.
- Closing expected in Q4 2026, subject to stockholder approvals and regulatory clearances.
- Passage shareholders receive contingent value rights for potential milestone payments from pediatric gene therapy programs sublicensed to Gemma Biotherapeutics.
Financial Impact
Massive dilution for existing Passage shareholders — ownership stake reduced to ~7% of the combined entity. The PIPE of over $100M provides funding into 2028 but primarily benefits Remix stakeholders. CVRs offer speculative upside from legacy gene therapy milestones.
Risk Factors
- Failure to obtain stockholder or regulatory approvals could terminate the merger.
- REM-422 clinical data may disappoint, undermining the combined company's valuation.
- PIPE investors may back out if conditions are not met, jeopardizing funding.
- CVR holders may never receive payments if legacy programs fail to generate milestones.
- Integration risks and potential shareholder lawsuits could delay or derail the transaction.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 425 Filing (Primary) | 0001104659-26-077350 |
| Document: 0001104659-26-077350-index-headers.html | 0001104659-26-077350 |
| Document: 0001104659-26-077350-index.html | 0001104659-26-077350 |
| Document: 0001104659-26-077350.txt | 0001104659-26-077350 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 3, 2026 29d ago | S-4/A / 425 | $4.75 $5.00 | ▼ −5.26% | ▼ −6.41% | $4.33 (+8.84%) |
Sep 3, 2026 29d ago | 8-K | $4.75 $5.00 | ▲ +5.26% | ▲ +6.41% | $4.33 (−8.84%) |
Jun 24, 2026 14w ago | 425 | $4.33 $4.58 | ▼ −5.77% | ▼ −4.21% | $4.33 (+0.00%) |
Jun 24, 2026 14w ago | 425 | $4.33 $4.58 | ▼ −5.77% | ▼ −4.21% | $4.33 (+0.00%) |
Jun 24, 2026 14w ago | 8-K | $4.33 $4.58 | ▼ −5.77% | ▼ −4.21% | $4.33 (+0.00%) |
May 27, 2026 18w ago | 8-K | $5.71 $6.00 | ▼ −5.08% | ▼ −4.76% | $4.33 (+24.17%) |
Apr 20, 2026 23w ago | 8-K | $6.25 $5.71 | ▼ −8.64% | ▼ −9.55% | $4.33 (−30.72%) |
Apr 20, 2026 23w ago | Press Release | $6.25 $5.71 | ▼ −8.64% | ▼ −9.55% | $4.33 (−30.72%) |
Apr 7, 2026 25w ago | DEFA14A | $8.22 $10.86 | ▲ +32.20% | ▲ +26.87% | $4.33 (−47.29%) |
Mar 3, 2026 30w ago | Press Release | $8.00 $8.51 | ▲ +6.38% | ▲ +6.85% | $4.33 (−45.88%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access